Men finally given access to key osteoporosis drug

06 Jul 2018

Thousands of men previously denied access to the osteoporosis drug teriparatide will now be able to get the medication following an NHS 70th anniversary push to make a range of innovative new treatments available.

The decision to make the drug more widely available was due, in part, to influencing work from National Osteoporosis Society Trustees and clinical advisers.

Teriparatide, a parathyroid hormone treatment, was previously only available for use in women and is an effective medication for treating osteoporosis, particularly among those who have suffered vertebral fractures.

Around 4,000 men will now benefit from access to this drug every year.

Ali Doyle, Head of Clinical Practice at the National Osteoporosis Society, welcomed the move.

“One in every five men in the UK will break a bone as a result of osteoporosis, so it’s fantastic that they will finally be able to benefit from this important osteoporosis treatment. The National Osteoporosis Society has long been an advocate of improved access to treatment for all and the fact that this treatment has been prioritised for funding is a real step forward.”

Professor Neil Gittoes, National Osteoporosis Society Trustee and Consultant and Honorary Professor of Endocrinology at the University of Birmingham, said the work to widen access of teriparatide to men was "a great example of not accepting inequity of access to an important therapy and sticking with the cause."

"This initiative addresses a big problem,  and now men across England should be assured that they have legitimate access to the most powerful anti-fracture agents available to us.

The Charity has been instrumental in providing further momentum to drive this through. We have managed to bring this about over a very short time frame by working collaboratively yet in a very focused manner to ensure that we did not lose the wave of energy we perceived from NHS England to support this piece of work."

 Read more about teriparatide

 

Comments (0)

Add Comment

Login with social media, or with your account, to post your comment